People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

If not administered properly, the GLP-1 medication can cause nausea, abdominal pain, and cramps, possibly leading to dehydration. The doses are normally taken a week apart, so not waiting long enough ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Not all weight loss programs are made equal—to reach a healthy, sustainable weight, personalized programs offer the best ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Promising new research suggests GLP-1 medications like Ozempic and Wegovy may reduce alcohol cravings and consumption in ...